ContraFect Corp - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CFRX Nasdaq 2834 https://www.contrafect.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ContraFect Corp

CFRX: Results from Interim Futility Analysis in July 2022… - May 26th, 2022 11:20 am
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman - May 23rd, 2022 12:00 pm
ContraFect Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 20th, 2022 12:30 pm
ContraFect Reports First Quarter 2022 Financial Results and Provides Business Update - May 16th, 2022 11:30 am
Keynotes, Educational Panels and 88 Companies to Present at the Planet MicroCap Showcase on May 3-5, 2022 at Bally's Hotel & Casino in Las Vegas, NV - Apr 27th, 2022 1:00 pm
ContraFect Data Presentations at the 32nd Annual ECCMID Meeting Highlight the Potential of Engineered Lysin CF-370 to Improve Clinical Outcomes and Suppress Antimicrobial Resistance Compared to Antibiotics Alone - Apr 27th, 2022 12:00 pm
ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID Meeting - Apr 18th, 2022 11:30 am
CFRX: Futility Analysis for DISRUPT Trial in 1H22… - Apr 4th, 2022 11:15 am
ContraFect Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Update - Mar 24th, 2022 12:00 pm
ContraFect to Present at the Maxim Group 2022 Virtual Growth Conference - Mar 21st, 2022 12:30 pm
ContraFect Corporation (NASDAQ:CFRX): When Will It Breakeven? - Mar 2nd, 2022 9:20 am
ContraFect to Present at the SVB Leerink 11th Annual Global Healthcare Conference - Feb 10th, 2022 12:30 pm
ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Serious MRSA Lung Infections Associated with Cystic Fibrosis - Jan 6th, 2022 9:05 pm
How Much Of ContraFect Corporation (NASDAQ:CFRX) Do Institutions Own? - Jan 1st, 2022 12:23 pm
Compassionate Use Case Study Demonstrating the Potential of Investigational Direct Lytic Agent Exebacase to Treat MRSA Bacteremia in Pediatric Populations Published in Clinical Infectious Diseases - Dec 20th, 2021 2:00 pm
CFRX: Direct Lytic Agents Show In Vitro Activity Against Gram-Negative Pathogens… - Nov 30th, 2021 10:52 am
ContraFect Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Nov 15th, 2021 12:30 pm
ContraFect’s New Data Presented at NACFC Demonstrate Potential of Direct Lytic Agents to Treat Pulmonary Infections in Patients with Cystic Fibrosis - Nov 9th, 2021 12:30 pm
We Think ContraFect (NASDAQ:CFRX) Needs To Drive Business Growth Carefully - Nov 1st, 2021 11:11 am
ContraFect to Present Data on the Potential of DLAs to Treat Pulmonary Infections in Cystic Fibrosis Patients - Oct 26th, 2021 11:30 am